Prostate Cancer Screening With Abbreviated MRI Protocol

Launched by MASARYK MEMORIAL CANCER INSTITUTE · Oct 30, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to screen for prostate cancer using a special type of MRI called biparametric MRI. Prostate cancer is very common in men, but current screening methods, like the PSA blood test, often find cancers that aren't serious and can lead to unnecessary worry and treatment. The goal of this study is to see if this new MRI method can better identify serious prostate cancers while avoiding the detection of less dangerous ones. Researchers want to see if this approach works well in the Czech population and to gather data that might help improve future screenings.

To join this trial, participants need to be men aged 50 to 69 who are generally healthy and have not had any recent prostate tests or procedures. They'll need to sign consent and be able to undergo the MRI and any other required procedures. Participants can expect to have an MRI scan without the need for contrast dye, which makes the process quicker and more comfortable. This study is important because, if successful, it could lead to better screening methods for prostate cancer, similar to the established screenings for breast cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Age 50-69 years
• • Life expectancy over 10 years
• • Ability to undergo all planned procedures (without contraindications to MRI or biopsy)
• • No known prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction)
• • No PSA test or prostate MRI in the past 2 years.
• • No signs of prostatitis or urinary tract infection in the past 6 months.
• • Signed informed consent.
• Exclusion Criteria:
• • Contraindications to MRI
• • Hip replacement
• • Known BRCA1/BRCA2 mutation